Related Experiment Video
Updated: Jun 6, 2026

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Therapeutic molecular targets in human chondrosarcoma.
Nuor Jamil1, Sarah Howie, Donald M Salter
1Osteoarticular Research Group, Centre for Molecular Medicine, University of Edinburgh, Edinburgh, UK. N.S.M.Jamil@sms.ed.ac.uk
International Journal of Experimental Pathology
|November 17, 2010
Summary
Chondrosarcomas are rare malignant cartilage tumors resistant to conventional treatments. Targeting molecular pathways to induce apoptosis offers a promising strategy to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Chondrosarcomas are malignant tumors originating from cartilage.
- These tumors exhibit poor response to chemotherapy and radiotherapy.
- Current treatment relies on surgical resection, with limited success in high-grade cases.
Purpose of the Study:
- To review molecular targets regulating chondrocyte apoptosis.
- To discuss experimental evidence for targeting apoptosis in chondrosarcoma.
- To explore novel therapeutic strategies for chondrosarcoma treatment.
Main Methods:
- Literature review of molecular targets.
- Analysis of experimental data on apoptosis induction.
- Discussion of therapeutic implications.
Main Results:
- Identification of key molecular pathways controlling chondrocyte apoptosis.
- Evidence suggests that enhancing apoptosis can improve chondrosarcoma treatment efficacy.
- Potential targets for novel therapeutic interventions were highlighted.
Conclusions:
- Inducing apoptosis in chondrosarcoma cells is a potential therapeutic avenue.
- Targeting molecular regulators of apoptosis may overcome resistance to current therapies.
- Further research into these molecular targets could lead to improved patient outcomes.
Related Concept Videos
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
